Haloperidol
FGA • Brands: Haldol
Last reviewed: 2025-09-23
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: 5–20 mg/day
Mechanism (brief)
Potent dopamine D2 receptor antagonism; minimal anticholinergic.
Metabolism & Half‑life
- Metabolism: Hepatic (CYP3A4/2D6).
- Half‑life: ~21 h (oral); decanoate depot longer.
Therapeutic Drug Monitoring (TDM)
Recommended: No
View labelExact
Long‑acting injectable (LAI)
Monitoring highlights
- EPS monitoring; QTc caution — Periodically
In‑depth reading
- Haloperidol decanoate dosing and conversion: review — Review (2018)
- Establishing a dose–response relationship for haloperidol decanoate — Psychiatric Bulletin (2005)
- Haloperidol serum concentrations and D2 receptor occupancy during low‑dose treatment with haloperidol decanoate — International Clinical Psychopharmacology (1997)
- Haloperidol and reduced haloperidol plasma concentrations after a loading dose regimen with haloperidol decanoate — Progress in Neuro‑Psychopharmacology and Biological Psychiatry (1996)
- D2 dopamine receptor occupancy during low‑dose treatment with haloperidol decanoate — American Journal of Psychiatry (1995)
Sources
- Haloperidol label — DailyMed (2025)